CSL Of Australia To Update Production Plants For $262 Million
This article was originally published in PharmAsia News
Australia's CSL said it plans to build a new production plant in the state of Victoria as part of a $262 million, four-year plan to update facilities
You may also be interested in...
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.